OBJECTIVE: To study the clinicopathological significance of heparanase and @entity7 expression in NSCLC. METHODS: Eighty-five lung samples were studied. Each sample was divided into two parts, one used for heparanase mRNA detection by reverse transcription PCR and the other for @entity7 detection by immunohistochemistry. RESULTS: (1) The expressions of heparanase mRNA and @entity7 were higher in NSCLC than in benign @entity358 (P < 0.05). (2) The expression of heparanase mRNA was higher in cases with lymph-node invasion, @entity3 , stage III and IV diseases, low-differentiation, and @entity420 , as compared to cases without lymph-node invasion and @entity3 , with stage I and II diseases, higher and moderate differentiation, and @entity1544 (P < 0.05). Its expression was higher in @entity5 larger than 5 cm in size (P < 0.05). (3) The expression of @entity7 was higher in cases with lymph-node invasion, @entity3 , and stage III and IV disease, as compared to cases without lymph-node invasion and @entity3 , and with stage I and II diseases (P < 0.05). (4) There was no significant correlation between heparanase and @entity7 expression (P > 0.05). CONCLUSIONS: Heparanase and @entity7 are associated with NSCLC invasion and @entity3 , and may be used to evaluate NSCLC @entity3 status. Heparanase and @entity7 promote NSCLC invasion and @entity3 by independent mechanisms. Detection of these two markers may improve the sensitivity and specificity of the measurement of NSCLC metastatic potential.

[Heparanase and XXXX expression in non-small-cell lung cancer].

@entity7 :: ('7422', 'Gene') :: ['VEGF'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity1544 :: ('MESH:D018307', 'Disease') :: ['squamous cell cancer'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary diseases'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity7 :: (7422,Gene) :: ['vascular endothelial growth factor']
